Sanyou Biopharmaceuticals Co. Ltd. has prepared and tested new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic agent through linker reported to be useful for the treatment of lung and stomach cancer.

Antibody-drug conjugates (ADCs) comprising an antibody targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug have been described in a Shanghai Pharmaceuticals Holding Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has patented new crystalline salt forms of poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Vanderbilt University has identified new 1-heteroarylazetidine-3-heteroarylmethylcarboxamide 5-HT2B receptor antagonists reported to be useful for the treatment of myocardial infarction, systemic sclerosis and pulmonary arterial hypertension.

Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.

Beijing Innocare Pharma Tech Co. Ltd. has synthesized new antibody-drug conjugates comprising antibody or antigen-binding fragment covalently linked to eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducer potentially useful for the treatment of cancer.

Ono Pharmaceutical Co. Ltd. has synthesized bridged bicyclic compounds acting as endosomal/lysosomal proton channel TMEM175 activators. As such, they are described as potentially useful for the treatment of inflammatory disorders, lysosomal storage diseases, autoimmune disease and Parkinson’s disease.

University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the treatment of neurological and psychiatric disorders.

Work at Pheon Therapeutics Ltd. has led to the development of new antibody-drug conjugates comprising an antibody or antigen binding fragment targeting CUB domain-containing protein 1 (CDCP1) covalently linked to cytotoxic drug. They are intended for use in the treatment of cancer.

Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.